SCHEMBL1658542

SCHEMBL1658542

Cc1ccc(C#Cc2ncc(C(=O)NC3CCCC3)s2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.49
NPC1 O15118 6/20 0.49
HPGD P15428 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C19 P33261 2/20 0.49
GRM5 P41594 3/20 0.46
CNR1 P21554 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
S1PR1 P21453 1/20 0.45
ACVR2A P27037 1/20 0.44
TGFBR2 P37173 1/20 0.44
ALDH1A1 P00352 2/20 0.44
TSHR P16473 3/20 0.43
TP53 P04637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ESR1 P03372 1/20 0.42
ESRRG P62508 1/20 0.42
ESR2 Q92731 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1659667 0.88 RAB9A (0.49) RAB9ANPC1HPGDSMN1; SMN2CYP1A2
SCHEMBL1657965 0.88 GRM5 (0.60) RAB9ANPC1HPGDCYP1A2CYP2C19
SCHEMBL1658005 0.87 GRM5 (0.61) RAB9ANPC1HPGDSMN1; SMN2CYP1A2
SCHEMBL1658409 0.86 RAB9A (0.50) RAB9ANPC1HPGDSMN1; SMN2GRM5
SCHEMBL1657252 0.83 GRM5 (0.57) RAB9ANPC1HPGDSMN1; SMN2GRM5
SCHEMBL1657873 0.81 RAB9A (0.48) RAB9ANPC1HPGDSMN1; SMN2CYP1A2
SCHEMBL1657349 0.80 L3MBTL1 (0.51) RAB9ANPC1GRM5MEN1KMT2A
SCHEMBL1657931 0.80 GRM5 (0.61) RAB9ANPC1SMN1; SMN2GRM5MEN1
SCHEMBL12789169 0.79 CNR1 (0.55) RAB9ANPC1HPGDSMN1; SMN2CYP1A2
SCHEMBL1657505 0.78 GRM5 (0.50) RAB9ANPC1SMN1; SMN2CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440837-B2 2-substituted-ethynylthiazole derivatives and uses of same H. LUNDBECK A/S (DK) 2013-05-14 US claimed
EP-2490541-A1 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME H. Lundbeck A/S (DK) 2012-08-29 EP claimed
WO-2011050063-A1 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2011-04-28 WO claimed
US-20110092475-A1 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2011-04-21 US claimed
US-20130231321-A1 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2013-09-05 US disclosed
US-20130231321-A1 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2013-09-05 US disclosed
US-8440837-B2 2-substituted-ethynylthiazole derivatives and uses of same H. LUNDBECK A/S (DK) 2013-05-14 US disclosed
US-8440837-B2 2-substituted-ethynylthiazole derivatives and uses of same H. LUNDBECK A/S (DK) 2013-05-14 US disclosed
US-20110092475-A1 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231321-A1 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME SULT1E1, SULT2A1, SULT1A1 RAB9A 1701/4885NPC1 508/4885HPGD 1114/4885
US-20110092475-A1 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME SULT1E1, SULT2A1, SULT1A1 RAB9A 1701/4885NPC1 508/4885HPGD 1114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.